| Aduro Biotech is an immunotherapy company focused on the discovery, development and commercialization of therapies for the treatment of patients with diseases. Co.'s product candidates in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways are being investigated in cancer, autoimmune and inflammatory diseases. Co.'s key STING pathway activator product candidate, ADU-S100 (MIW815), is designed to selectively modulate innate and adaptive immune responses to enhance immune control in oncology. Co.'s anti-APRIL antibody product candidate, BION-1301, is designed to suppress the autoimmune response in patients with IgA nephropathy. We show 24 historical shares outstanding datapoints in our ADRO shares outstanding history coverage, used to compute ADRO market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ADRO market cap history over the course of time is important for investors
interested in comparing ADRO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ADRO versus a peer is one thing; comparing
ADRO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ADRO can fluctuate over the course of history.
With this page we aim to empower investors researching ADRO by allowing them to research the ADRO market cap history.